Abstract
The EPOCH trial investigated the potential benefit of adding transarterial radioembolization (TARE) with yttrium-90 glass microspheres to second-line chemotherapy in patients with liver-dominant metastatic colorectal cancer (mCRC). Post-hoc analyses evaluated the effect of TARE treatment day post calibration on clinical and safety outcomes.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
